TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: CoP pathlength decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in maximal diameter of the most suspicious lymph node (LN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of depression/sadness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interrater reliability of classification schemes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score at rest and after ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from locoregional recurrence (LRR)
Endpoint domain: Mortality/survival
Primary endpoint: Average retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of metamorphopsia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Cortisol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: less sternal movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery from pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: median stenosis degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total restenosis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL-gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of VTE
Endpoint domain: Mortality/survival
Primary endpoint: Risk of hematoma enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitemia development
Endpoint domain: Adverse events/effects
Primary endpoint: Complete absence of bleeding/spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predefined HMB response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in volume of the three largest UF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual analog pain scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of invasive ventilation/death at 14 days
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative probability of confirmed negative nasopharyngeal swabs at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the ratio of urinary albumin to creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of apoA1 in HDL subspecies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Annualized relapse rates (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from 6-month confirmed disability worsening (CDW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased proportions free of MRI disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of physical activity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation coefficients for vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation coefficients for sedentary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of planned reintervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Seroprotection rate against 7 serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels against serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychological burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: insertional intracochlear trauma scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to get out of bed post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry eye symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescription rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Knowledge of ASD
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Extruded NaOCl/debris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetrability of NaOCl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HAM-D17 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of responders (decrease in HAM-D17 total score by at least 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life and daily functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Length of specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of residual fragment of sigmoid colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour ASPECTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good clinical outcome (day 90 modified Rankin Scale score 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: perceived health scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: new caries development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative peak levels of myoglobin, creatine kinase isoform and hypersensitive troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean stratum corneum hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: EAIRs of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: EAIRs of AEs leading to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: mean improvement in the SLE Disease Activity Index 2000
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HFS CTCAE grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HFS effectiveness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of retained material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lactate concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cortisol concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of histologic sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue acquisition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual incidence rate of PsA
Endpoint domain: Mortality/survival
Primary endpoint: commission error reduction in go/no-go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma AG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AG/UAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache intensity (area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 rates at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-CRP <2.6 at Weeks 12 and 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: benefits for cardiovascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of tonsillitis attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of assessed symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-min time trial power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak swelling reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Next Treatment (TTNT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of death or dependency at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in PSQI score (sleep quality)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in SDS score (depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Six-month percent strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: stool hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of bowel gas restlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stomach appearance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median QALY
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: triggering of sBCRL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the CanRisk tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ΔF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peak discharge rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incubation period (P100-L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude (P100-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year incidence of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure rate of TADs
Endpoint domain: Mortality/survival
Primary endpoint: DADDS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pain descriptors on the McGill scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain index on the McGill scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: goal specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 48-h CO exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maternal PM2.5 exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to decrease core temperature to less than 38.0 °C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BP-related disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of fatal and nonfatal suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Daytime sleepiness (ESS score)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: RS functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection rates of pulmonary nodules > 50 mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rates of pulmonary nodules < 50 mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of Covid-19
Endpoint domain: Mortality/survival
Primary endpoint: SHBG levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total testosterone decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of composite pregnancy complications
Endpoint domain: Adverse events/effects
Primary endpoint: Ambulation at 3 to 3.5 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Same-day discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum standardized uptake value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMD of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: BMD of the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Vitamin D deficiency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: relief from lameness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint flexibility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of needle visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IJV posterior wall puncture
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Modified-Kupperman index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Risk of CIB (Critical Illness Bleeding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of overt GI bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lifetime nonmedical prescription opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degrees of SSAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: telogen hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of hairs shed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for add-on medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: log10 of viral load values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: undetected viral load (≤20 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of ADR reports per patient
Endpoint domain: Adverse events/effects
Primary endpoint: DGE incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triceps fold measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper arm circumferences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repeat ED use rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: decreased risk of CVD
Endpoint domain: Mortality/survival
Primary endpoint: Change in nursing practice towards a least-restraint policy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: women's experiences of early labour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum load at failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total normalized elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in EQ-5D-Y scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hemagglutination inhibition antibody geometric mean ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing and binding antibody responses to RSV A2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coefficient of variation of within‐laboratory imprecision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linearity values for Elecsys hGH and IGF‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference between Elecsys hGH and IRMA, and Elecsys IGF‐1 and IRMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean plasma citrulline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Olfactory test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal function assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects on nasal health measures
Endpoint domain: Adverse events/effects
Primary endpoint: Composite kidney outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: jumping power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plantar flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plantar flexion rate of force development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional improvements (FMA and ARAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sense of vivid movement of the stroke-impaired upper limb
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall number of ovulatory cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Hormonal profile improvement (serum LH, FSH, testosterone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Preventive cardiovascular care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depressive symptoms decline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: daily functioning improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MOF (major osteoporotic fracture)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: median productivity (wRVU/hour)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain Pressure Threshold (PPT) at upper trapezius muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM) in extension, left and right lateral flexion, and left rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in understanding of clinical utility
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Favorable outcome (GOS-E ≥ 5)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-efficacy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diabetes self-management effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum AAA diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ART initiation in ≤7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ART initiation in ≤28 days and retention in care at 8 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Euroquol score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of clinical‐CT index in diagnosing NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-for-age z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CRC risk associated with circulating UCB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase in food insecurity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Increase in mothers' depression and anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mortality by Day 60
Endpoint domain: Mortality/survival
Primary endpoint: vocalisations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conversations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with the RESP-FIT + SAMS mHealth intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status